NasdaqCM - Nasdaq Real Time Price USD

RedHill Biopharma Ltd. (RDHL)

2.0000

+0.0300

+(1.52%)

At close: May 12 at 4:00:00 PM EDT

2.1700

+0.17

+(8.50%)

Pre-Market: 8:37:27 AM EDT

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it had won its attachment petition to the Court in South Korea on Kukbo Co. Ltd's ("Kukbo") assets, following the approximately $8.25 million plus legal fees and costs summary judgment ruling in RedHill's favor by the New York Supreme Court.

PR Newswire 1 hour ago

RDHL
+1.52%
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its support of an independent medical education grant that includes a new two-part H. Pylori CME program, developed by Medscape and designed to advance clinical knowledge and improve patient outcomes. The first part of the program, a livestreamed event entitled "Let's Get Social About H. pylori Management" led by William Chey, MD, Vivian Asamoah, MD and Shailja Shah, MD, MPH

PR Newswire 11 days ago

RDHL
+1.52%
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the China National Intellectual Property Administration ("CNIPA") has formally allowed a critical use of composition-of-matter patent for RedHill's proprietary investigational compound RHB-107 (upamostat), a potential oral treatment for COVID-19 (patent application No. 202311591091.6).

PR Newswire 15 days ago

HPHA.F

RDHL
+1.52%
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company received a written notification (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated April 15, 2025, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1) (the "Rule").

PR Newswire 25 days ago

RDHL
+1.52%
RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the new publication[2] of positive in vivo data, in the journal Diabetes, Metabolic Syndrome and Obesity, in an article entitled "Opaganib Promotes Weight Loss and Suppresses High-Fat Diet (HFD)-Induced Obesity and Glucose Intolerance". The data indicates that opaganib[3] effectively suppresses the loss of metabolic control in mice on a HFD, suggesting that opaganib, alone a

PR Newswire 27 days ago

RDHL
+1.52%
RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full-year 2024 financial results and operational highlights and associated filing of its annual report on Form 20-F for the year ended December 31, 2024.

PR Newswire last month

RDHL
+1.52%
Surrey loses rush-hour taxis to thousands of school runs

Workers in Surrey have been left unable to book a taxi first thing in the morning because firms are too busy ferrying pupils to state schools.

The Telegraph last month

RDHL
+1.52%
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plan to submit a UK Marketing Authorisation Application (MAA) for Talicia for treatment of helicobacter pylori (H. pylori) infection under the Medicines and Healthcare products Regulatory Agency's (MHRA) International Recognition Procedure (IRP), a fast-track regulatory process for UK drug approvals based on a recognized reference approval. Utilizing the U.S. Food and Dr

PR Newswire last month

RDHL
+1.52%
RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced plans to advance its groundbreaking late-stage program for Crohn's disease (CD) with initiation of an innovative Phase 2 study of RHB-204 in Mycobacterium avium subspecies paratuberculosis-positive (MAP+) moderate to severe CD, utilizing novel endpoints and the new gold standard in imaging techniques, pending Type C discussions on path to FDA approval with guidance from FDA

PR Newswire 2 months ago

RDHL
+1.52%
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the presentation of a business update by Guy Goldberg, RedHill's Chief Business Officer, highlighting recent significant corporate activity, R&D advances and commercial progress with Talicia, at the Sachs Associates' 18th Annual European Life Sciences CEO Forum in Zurich.

PR Newswire 2 months ago

RDHL
+1.52%
RedHill and Hyloris sign agreement for Bekinda’s development

RedHill will obtain an upfront payment from Hyloris and may receive up to $60m in milestone payments.

Pharmaceutical Technology 2 months ago

HYL.BR

RDHL
+1.52%
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America (the "Agreement"), with Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) ("Hyloris") for RedHill's RHB-102 (Bekinda®).

PR Newswire 2 months ago

RDHL
+1.52%
RedHill Biopharma launches trial of combination therapy for prostate cancer

The trial is being financially backed by Bayer and the Ramsay Hospital Research Foundation.

Clinical Trials Arena 3 months ago

RDHL
+1.52%
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the initiation of a Phase 2 clinical study to evaluate the efficacy of opaganib[3] in combination with darolutamide[4] in men with metastatic castrate-resistant prostate cancer (mCRPC). Financially supported by Bayer (ETR: BAYN) and the Ramsay Hospital Research Foundation, the 80-patient placebo-controlled randomized study is designed to test the potentially enhancing effect

PR Newswire 3 months ago

RDHL
+1.52%
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the coverage of Talicia by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without the requirement for prior therapeutic steps or authorizations, for both treatment-naïve and treatment-experienced patients, effective as of January 1, 2025.

PR Newswire 3 months ago

RDHL
+1.52%
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced positive results from new in vivo studies of opaganib[1] as a treatment for gastrointestinal acute radiation syndrome (GI-ARS), undertaken as part of the U.S. government's Radiation and Nuclear Countermeasures Program (RNCP) product pipeline development contract awarded to opaganib, that further confirm opaganib's protective activity in models of GI-ARS.

PR Newswire 4 months ago

RDHL
+1.52%
RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court

RedHill Biopharma (RDHL) announced that the Company has been awarded approximately $8 million, plus costs in a summary judgment by the Supreme Court of the State of New York, New York County, in its legal proceedings against Kukbo Co. Ltd., domiciled in South Korea. The case refers to Kukbo’s failure to make agreed payments to RedHill, pursuant to a Subscription Agreement, dated October 25, 2021, and a subsequent Exclusive License Agreement, dated March 14, 2022, entered into by the two companie

TipRanks 5 months ago

RDHL
+1.52%
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has been awarded approximately $8 million (consisting of $6.5 million plus interest amounting to approximately $1.5 million), plus costs in a summary judgment by the Supreme Court of the State of New York, New York County (the "Court"), in its legal proceedings (Index number: 653200/2022) against Kukbo Co. Ltd. ("Kukbo"), domiciled in South Korea.

PR Newswire 5 months ago

RDHL
+1.52%
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has been selected to further elaborate on opaganib's[1] potential in a presentation to U.S. government representatives at the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) "Host Directed Therapeutics Industry Day". The meeting is scheduled to take place October 29-30, 2024, at the United States Paten

PR Newswire 6 months ago

RDHL
+1.52%
RedHill Biopharma and Duke Collaborate on Opaganib Development

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has announced a collaboration with Duke University School of Medicine to test the drug opaganib as a treatment for phosgene inhalation injury, a potential public safety threat. The partnership aims to advance opaganib development under FDA guidelines, addressing the lack of approved antidotes for this toxic industrial chemical. Opaganib’s broad potential applications and its ongoing evaluation by U.S. government programs highligh

TipRanks 6 months ago

RDHL
+1.52%

Performance Overview

Return	RDHL	MSCI WORLD (^990100-USD-STRD)
YTD	-70.01%	+2.46%
1-Year	-82.53%	+11.04%
3-Year	-99.79%	+40.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

RedHill Biopharma Ltd. (RDHL)

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Surrey loses rush-hour taxis to thousands of school runs

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill and Hyloris sign agreement for Bekinda’s development

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Biopharma launches trial of combination therapy for prostate cancer

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Biopharma and Duke Collaborate on Opaganib Development

Performance Overview